BNT116 is an intravenously administered RNA-lipoplex therapeutic cancer vaccine comprising six RNAs each encoding a tumor-associated antigen (TAA) frequently expressed in non-small cell lung cancer (NSCLC).

The phase 1 trial of LY3410738, a covalent mutant IDH inhibitor, in advanced IDH-mutant CCAs and other tumors was presented at the AACR Congress, paving the way for further outcome evaluation.

The latest clinical findings of Ianalumab were unveiled at the 2023 AACR Congress, demonstrating its potential effect and setting the stage for subsequent investigations.

On 14 Apr 2023, the clinical trial evaluating exarafenib (KIN-2787) in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma was reported at the AACR Congress.

On 15 Apr 2023, the efficacy and safety of adjuvant (adj) atezolizumab (atezo) from the Phase 2 LCMC3 study was reported at the AACR Congress.

Recently the clinical trial of Nivolumab, a PD-1 blockade, for the treatment of RR HL was reported at the ASCO Congress.

we are excited to announce the addition of clinical trial outcomes to Synapse Premium!